CXADR

CXADR

CXADR 詳細

Molecule Name
Calcium sensing receptor
分子の別称
CXADR,CAR,CAR4,6,HCAR
Drug Development Progress
治験薬の数5
市販薬剤の数6
研究&開発段階Approved
ターゲットの別称
Parathyroid cell calcium-sensing receptor 1,FHH,FIH,HHC,Receptors, Calcium-Sensing,Extracellular calcium-sensing receptor,hCasR,GPRC2A,Calcium Sensing Receptor,Parathyroid Ca(2+)-Sensing Receptor 1,Severe Neonatal Hyperparathyroidism,Calcium-Sensing Receptor,HYPOC1,NSHPT,PCaR1,EIG8,HHC1,CaSR,CAR,Hypocalciuric Hypercalcemia 1
バックグランド
Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human CXADR protein contains a signal sequence, a extracellular domain (ECD) with a V­ type (D1) and a C2­ type (D2) Ig­like domain, a  transmembrane segment and a intracellular domain. D1 is thought to be responsible for homodimer formation in trans within tight junctions, and is necessary and sufficient for adenovirus binding. Variants of CXADR are attached to the cell membrane by a GPI- anchor.

CXADR 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Encaleret sulfateMK-5442; JTT-305; BBP-305; CLTX-305Phase 3 ClinicalJapan Tobacco (Hong Kong) Ltd
Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal; Hypoparathyroidism
詳細
SHR-6508SHR-6508Phase 3 ClinicalShanghai Hengrui Pharmaceutical Co Ltd
Hyperparathyroidism, Secondary; Kidney Diseases; Renal Insufficiency, Chronic; Hyperparathyroidism
詳細
LNP-1892LNP-1892Phase 2 ClinicalLupin Ltd
Hyperparathyroidism
詳細
DS-9194bDS-9194bPhase 1 ClinicalDaiichi Sankyo Co Ltd
Osteoporosis
詳細
RT-102(Rani)RT-102Phase 1 ClinicalRani Therapeutics Holdings Inc
Osteoporosis
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
UpacicalcetSK-1403; AJT-240ApprovedAjinomoto Co Incウパシタ, UpasitaJapanHyperparathyroidism, SecondarySanwa Kagaku Kenkyusho Co Ltd2021-06-23
Hyperparathyroidism, Secondary
詳細
Parathyroid hormone (Shire)SHP-634; ALX-111; 423562; NPSP-795; rhPTH (1-84); SHP-635; rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558ApprovedShireNatpara, Preotact, NatparUnited StatesHypoparathyroidismNps Pharmaceuticals, Inc2006-04-24
Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Hypoparathyroidism; Hyperparathyroidism; Plaque psoriasis
詳細
Cinacalcet HydrochlorideAMG-073.HCl; NPS-1493; AMG-073; KRN-1493ApprovedAmgen IncParareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/MimparaUnited StatesHypercalcemia; Hyperparathyroidism, SecondaryAmgen Inc2004-03-08
Hyperparathyroidism, Secondary; Rejection of renal transplantation; Hypophosphatemia; Edema, Cardiac; Nephrosis; Renal Insufficiency; Parathyroid Neoplasms; Hypercalcemia; Kidney Diseases; Hyperparathyroidism, Primary; Prostatic Neoplasms; Osteomalacia; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder
詳細
Etelcalcetide HydrochlorideONO-5163; KAI-4169; AMG-416; KAI-4169-HClApprovedAmgen IncParsabivEUHyperparathyroidism, SecondaryAmgen Europe Bv2016-11-11
Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic; Kidney Failure, Chronic
詳細
Strontium RanelateS-12911; S-12911-2; FK-481ApprovedLaboratoires ServierOsseor, Protos, Protelos, 欧思美Mainland ChinaOsteoporosis, PostmenopausalLes Laboratoires Servier2004-09-20
Osteoporosis, Postmenopausal
詳細
EvocalcetKHK-7580; MT-4580ApprovedMitsubishi Tanabe Pharma CorpOrkediaJapanHyperparathyroidism, SecondaryKyowa Hakko Kirin Co Ltd2018-03-23
Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism
詳細